Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

SML2673

Sigma-Aldrich

Deferasirox

≥98% (HPLC)

Sinonimo/i:

4-[3,5-bis(2-Hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

10 MG
CHF 113.00
50 MG
CHF 455.00

CHF 113.00

Check Cart for Availability
Richiedi un ordine bulk
Tutte le immagini(1)

Scegli un formato

Cambia visualizzazione
10 MG
CHF 113.00
50 MG
CHF 455.00

About This Item

Formula empirica (notazione di Hill):
C21H15N3O4
Numero CAS:
201530-41-8
Peso molecolare:
373.36
Numero MDL:
MFCD09951804
Codice UNSPSC:
12352200
NACRES:
NA.77

CHF 113.00

Check Cart for Availability
Richiedi un ordine bulk

Saggio

≥98% (HPLC)

Stato

powder

Colore

white to beige

Solubilità

DMSO: 2 mg/mL, clear

Temperatura di conservazione

2-8°C

Stringa SMILE

N2(N\C(=C4\C=CC=CC\4=O)\N\C\2=C3\C=CC=CC\3=O)c1ccc(cc1)C(=O)O

InChI

1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,22-23H,(H,27,28)/b19-15-,20-16+
FMSOAWSKCWYLBB-VBGLAJCLSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Applicazioni

Deferasirox has been used as an iron chelator to test its effect on clofazimine mediated growth inhibition and rescue in Salmonella typhimurium.[1]

Azioni biochim/fisiol

Deferasirox belongs to the N-substituted bis-hydroxyphenyl-triazole family of tridentate iron chelators.[2]
Deferasirox is an orally available iron chelator used clinically for reduction of chronic iron overload in diseases such as β-thalassemia.
Orally available iron chelator

Pittogrammi

Exclamation markEnvironment
GHS07,GHS09

Avvertenze

Warning

Indicazioni di pericolo

H302,H400

Consigli di prudenza

P273 - P301 + P312 + P330

Classi di pericolo

Acute Tox. 4 Oral - Aquatic Acute 1

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
0000245905
0000198000
0000183094

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Claudia Bollig et al.
The Cochrane database of systematic reviews, 8, CD007476-CD007476 (2017-08-16)
Thalassaemia is a hereditary anaemia due to ineffective erythropoiesis. In particular, people with thalassaemia major develop secondary iron overload resulting from regular red blood cell transfusions. Iron chelation therapy is needed to prevent long-term complications.Both deferoxamine and deferiprone are effective;
Nesma Ahmed Safwat et al.
Pediatric research, 89(1), 185-190 (2020-06-17)
The genetic variants of the receptor for advanced glycation end products (RAGE) gene have been associated with vascular disease risk. The objective of this work was to explore the association of three single-nucleotide polymorphisms (SNPs) of RAGE gene (374T/A, 429T/C
Abbas Rahdar et al.
Life sciences, 270, 119146-119146 (2021-02-06)
Deferasirox (DFX) was formulated into oil-in-water microemulsions in the presence of pluronicto improve its oral bioavailability. The size of the DFX-loadedmicroemulsions system measured by dynamic light scattering (DLS) was about 9 nm. The anti-proliferative and anti-lipid peroxidation effects of DFX and
Omid Reza Zekavat et al.
Journal of pediatric hematology/oncology, 43(1), e26-e28 (2020-09-15)
This study was performed on patients with transfusion-dependent beta-thalassemia (TDT) to investigate the effect of HFE gene mutations of iron overload in a large group of patients with TDT major and its relationship with heart and liver T2* magnetic resonance
Wataru Goto et al.
BMC cancer, 20(1), 1215-1215 (2020-12-12)
Iron is required for the proliferation of cancer cells, and its depletion suppresses tumor growth. Eribulin mesylate (eribulin), a non-taxane microtubule inhibitor, disrupts the tumor microenvironment via vascular remodeling and obstruction of the epithelial-mesenchymal transition (EMT). Herein, we investigated the
Visualizza tutti i documenti correlati

Questions

Reviews

No rating value

Active Filters

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.